Want to see JP:4538 full AI Analyst Report?
4538 Stock Chart & Stats
¥2315.00
-¥64.00(-2.54%)
At close: 4:00 PM EST
¥2315.00
-¥64.00(-2.54%)
Day’s Range― - ―
52-Week Range¥1,990.00 - ¥2,530.00
Previous CloseN/A
Volume28.90K
Average Volume (3M)17.49K
Market Cap
¥19.95B
Enterprise Value¥39.64K
Total Cash (Recent Filing)¥4.57B
Total Debt (Recent Filing)¥26.31B
Price to Earnings (P/E)8.9
Beta0.58
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.96%
Share Statistics
EPS (TTM)256.65
Shares Outstanding9,451,169
10 Day Avg. Volume18,340
30 Day Avg. Volume17,486
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)0.58
Price to Sales (P/S)0.32
P/FCF Ratio-2.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthA sustained upward revenue trend indicates expanding demand for Fuso’s prescription medicines. The FY2026 acceleration provides a stronger top-line base, which can support operating leverage if production efficiency and pricing remain controlled.
Hospital-Focused Pharmaceutical PortfolioFocusing on hospital-oriented prescription products and injectables gives Fuso exposure to essential healthcare demand rather than discretionary consumption. This positioning can support recurring product usage and durable relevance within Japan’s regulated medical system.
Return To ProfitabilityThe return to positive net income shows that the company retained the ability to restore profitability after a difficult year. If revenue growth persists and cost pressures moderate, this recovery could provide a foundation for improved earnings resilience.
Bears Say
Rising LeverageThe faster increase in debt than equity has reduced balance-sheet flexibility. Higher leverage can constrain investment capacity and increase vulnerability if profitability weakens, making future earnings recovery more important to financial stability.
Persistently Weak Cash GenerationNegative operating and free cash flow despite FY2026 accounting profit signals weak earnings conversion. Ongoing working-capital or reinvestment demands could require greater borrowing and limit the company’s ability to self-fund growth.
Volatile Profitability And Margin PressureThe swing from loss to only modest profit, alongside lower gross and EBITDA margins, indicates limited earnings stability. Rising costs or pricing pressure could prevent revenue growth from translating into durable profit and cash-flow improvement.
Fuso Pharmaceutical Industries,Ltd. News
4538 FAQ
What was Fuso Pharmaceutical Industries,Ltd.’s price range in the past 12 months?
Fuso Pharmaceutical Industries,Ltd. lowest stock price was ¥1990.00 and its highest was ¥2530.00 in the past 12 months.
What is Fuso Pharmaceutical Industries,Ltd.’s market cap?
Fuso Pharmaceutical Industries,Ltd.’s market cap is ¥19.95B.
When is Fuso Pharmaceutical Industries,Ltd.’s upcoming earnings report date?
Fuso Pharmaceutical Industries,Ltd.’s upcoming earnings report date is Nov 05, 2026 which is in 79 days.
How were Fuso Pharmaceutical Industries,Ltd.’s earnings last quarter?
Fuso Pharmaceutical Industries,Ltd. released its earnings results on Aug 10, 2026. The company reported ¥75.3 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Fuso Pharmaceutical Industries,Ltd. overvalued?
According to Wall Street analysts Fuso Pharmaceutical Industries,Ltd.’s price is currently Overvalued.
Does Fuso Pharmaceutical Industries,Ltd. pay dividends?
Fuso Pharmaceutical Industries,Ltd. pays a Semiannually dividend of ¥45 which represents an annual dividend yield of 3.96%. See more information on Fuso Pharmaceutical Industries,Ltd. dividends here
What is Fuso Pharmaceutical Industries,Ltd.’s EPS estimate?
Fuso Pharmaceutical Industries,Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fuso Pharmaceutical Industries,Ltd. have?
Fuso Pharmaceutical Industries,Ltd. has 9,451,169 shares outstanding.
What happened to Fuso Pharmaceutical Industries,Ltd.’s price movement after its last earnings report?
Fuso Pharmaceutical Industries,Ltd. reported an EPS of ¥75.3 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.201%.
Which hedge fund is a major shareholder of Fuso Pharmaceutical Industries,Ltd.?
Currently, no hedge funds are holding shares in JP:4538
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Fuso Pharmaceutical Industries,Ltd.
Fuso Pharmaceutical Industries, Ltd. is a Japanese firm primarily involved in the development and commercialization of pharmaceutical goods. Their product range encompasses prescription medications, particularly injectables and solutions for artificial kidney dialysis, as well as various medical instruments and apparatus. Additionally, the company participates in real estate leasing. Established in 1937, Fuso Pharmaceutical's corporate headquarters are situated in Osaka, Japan.
Technical Analysis
Pharma Foods International Co., Ltd.
―
Wakamoto Pharmaceutical Co., Ltd.
―
Morishita Jintan Co., Ltd.
―
Nippon Chemiphar Co., Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―